CN104395324B - 咪唑并‑噁二唑和咪唑并‑噻二唑衍生物 - Google Patents

咪唑并‑噁二唑和咪唑并‑噻二唑衍生物 Download PDF

Info

Publication number
CN104395324B
CN104395324B CN201380029418.9A CN201380029418A CN104395324B CN 104395324 B CN104395324 B CN 104395324B CN 201380029418 A CN201380029418 A CN 201380029418A CN 104395324 B CN104395324 B CN 104395324B
Authority
CN
China
Prior art keywords
mmol
formula
methyl
reaction
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380029418.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104395324A (zh
Inventor
A·卡特勒帕尼
D·斯温南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of CN104395324A publication Critical patent/CN104395324A/zh
Application granted granted Critical
Publication of CN104395324B publication Critical patent/CN104395324B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380029418.9A 2012-06-05 2013-05-23 咪唑并‑噁二唑和咪唑并‑噻二唑衍生物 Active CN104395324B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261655544P 2012-06-05 2012-06-05
US61/655,544 2012-06-05
EP12170840.8A EP2671885A1 (en) 2012-06-05 2012-06-05 Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
EP12170840.8 2012-06-05
PCT/EP2013/001521 WO2013182274A1 (en) 2012-06-05 2013-05-23 Imidazo-oxadiazole and imidazo-thiadiazole derivatives

Publications (2)

Publication Number Publication Date
CN104395324A CN104395324A (zh) 2015-03-04
CN104395324B true CN104395324B (zh) 2017-09-12

Family

ID=46320789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380029418.9A Active CN104395324B (zh) 2012-06-05 2013-05-23 咪唑并‑噁二唑和咪唑并‑噻二唑衍生物

Country Status (9)

Country Link
US (2) US9932354B2 (OSRAM)
EP (2) EP2671885A1 (OSRAM)
JP (1) JP6167465B2 (OSRAM)
CN (1) CN104395324B (OSRAM)
AU (1) AU2013270979B2 (OSRAM)
CA (1) CA2875628C (OSRAM)
ES (1) ES2582556T3 (OSRAM)
IL (1) IL236076B (OSRAM)
WO (1) WO2013182274A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
MX2021002981A (es) 2018-10-05 2021-05-14 Forma Therapeutics Inc Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025029A2 (en) * 1993-04-26 1994-11-10 Janssen Pharmaceutica N.V. Use of sabeluzole in chronic neurodegenerative diseases
WO2002102800A1 (en) * 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
WO2003068754A1 (en) * 2002-02-13 2003-08-21 Astrazeneca Ab Therapeutic substituted indazole derivatives
CN1681815A (zh) * 2002-08-02 2005-10-12 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
CN1823064A (zh) * 2001-02-20 2006-08-23 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2－芳基氨基－嘧啶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
ES2431050T3 (es) * 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
PL2193133T3 (pl) * 2007-09-27 2016-01-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
JP5667058B2 (ja) * 2008-09-23 2015-02-12 ウィスタ ラボラトリーズ リミテッド 凝集したタウ分子に対するリガンド

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025029A2 (en) * 1993-04-26 1994-11-10 Janssen Pharmaceutica N.V. Use of sabeluzole in chronic neurodegenerative diseases
CN1823064A (zh) * 2001-02-20 2006-08-23 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2－芳基氨基－嘧啶
WO2002102800A1 (en) * 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
WO2003068754A1 (en) * 2002-02-13 2003-08-21 Astrazeneca Ab Therapeutic substituted indazole derivatives
CN1681815A (zh) * 2002-08-02 2005-10-12 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物

Also Published As

Publication number Publication date
US20180215770A1 (en) 2018-08-02
AU2013270979A1 (en) 2015-01-22
EP2855488A1 (en) 2015-04-08
IL236076B (en) 2019-05-30
ES2582556T3 (es) 2016-09-13
EP2855488B1 (en) 2016-04-13
IL236076A0 (en) 2015-02-01
AU2013270979B2 (en) 2017-04-27
CA2875628A1 (en) 2013-12-12
CA2875628C (en) 2021-01-19
EP2671885A1 (en) 2013-12-11
JP6167465B2 (ja) 2017-07-26
US10696690B2 (en) 2020-06-30
WO2013182274A1 (en) 2013-12-12
US20150175628A1 (en) 2015-06-25
CN104395324A (zh) 2015-03-04
US9932354B2 (en) 2018-04-03
JP2015522556A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
KR102824092B1 (ko) Cftr 강화제로서의 피롤로피리미딘
CN110869360B (zh) 作为rock抑制剂的苯乙酰胺类
JP5524171B2 (ja) キナーゼ阻害剤
KR102006684B1 (ko) Jak 억제제
CN111566103B (zh) 作为激酶抑制剂的氨基咪唑并吡嗪
CN107124882A (zh) 用于认知改善的新型化合物
HUE035919T2 (en) Macrocyclic pyridazinone derivatives
JP2010505957A (ja) 糖尿病に対して使用されるｎ−アリールピラゾール化合物
KR20080087070A (ko) 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
JP6229717B2 (ja) ガンマセクレターゼモジュレーターとしての縮合トリアゾール誘導体
CN104395324B (zh) 咪唑并‑噁二唑和咪唑并‑噻二唑衍生物
JP5713511B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
KR20230043103A (ko) 술폰아마이드 화합물
CN104364258A (zh) 用于治疗神经变性疾病的螺四氢-苯并噻吩衍生物
US20070072901A1 (en) 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5
JP2025520081A (ja) Ｔｒｐｍ３媒介性障害を治療するためのインドリジン誘導体
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant